UTHR
United Therapeutics Corporation
September 30, 2026 · intraday
- Rarity
- 4.90
- Peak move
- +15.12%
- Float cap
- $20.3B
United Therapeutics Corporation is a public benefit corporation that develops and commercializes therapies for people with serious diseases and unmet medical needs. It markets and sells treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, including Tyvaso, Remodulin, Orenitram, and Adcirca, as well as Unituxin for high-risk neuroblastoma. Its products are sold primarily in the United States, with some sales in select international markets.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 2 from SEC or newswire · 0 timed with the move- Key event
insider_saleUnited Therapeutics Chairperson/CEO Martine A. Rothblatt exercised 9,500 options at $117.76 and a trust sold 9,500 shares on September 28, 2026 at $472.43-$486.00 for about $4.57 million under a Rule 10b5-1 plan adopted November 7, 2025, leaving trust holdings at 324,443 shares.
- Key event
clinical_readoutA study published in The Lancet reported phase 3 ADVANCE OUTCOMES results for United Therapeutics' once-daily oral ralinepag in PAH, with 18% of ralinepag patients versus 36% of placebo patients having a first clinical worsening event among 687 patients, and adverse events causing discontinuation in 19% versus 3%.
- Key event
insider_saleUnited Therapeutics Chairperson & CEO Martine A. Rothblatt exercised 19,000 options at $117.76 and sold 9,500 shares on September 28, 2026 at prices from $472.43 to $486.00 for about $4.57 million under a Rule 10b5-1 plan, leaving 324,443 shares held.
SEC4 0001106578-26-000151Websec.gov analyst_ratingGoldman Sachs analyst Andrea Newkirk initiated coverage of United Therapeutics with a Sell rating and a $321 price target, arguing the shares trade above their historical valuation range as the core business shrinks and the IPF launch faces dosing and tolerability limits.
insider_saleA Form 4 disclosed that an insider at United Therapeutics sold shares worth $4,568,106.
insider_saleUnited Therapeutics Chairperson & CEO Martine A. Rothblatt exercised 9,500 options at $117.76 and a trust sold 9,500 shares on September 25, 2026 at $470.56-$478.95 for about $4.52 million under a Rule 10b5-1 plan adopted November 7, 2025, leaving trust holdings at 324,443 shares.